Drug Profile
NEO 212
Alternative Names: NEO-212Latest Information Update: 03 Jan 2024
Price :
$50
*
At a glance
- Originator NEONC Technologies
- Class Antineoplastics; Drug conjugates
- Mechanism of Action Alkylating agents; Apoptosis stimulants; DNA synthesis inhibitors; Ras protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Solid tumours
Most Recent Events
- 01 Nov 2023 Phase-I/II clinical trials in Solid tumours (Combination therapy, Metastatic disease, Second-line therapy or greater) in USA (PO) (NCT06047379)
- 21 Sep 2023 Neonc Technologies plans a phase I/II trial for Glioblastoma IDH-wildtype or uncontrolled Brain metastasis (Combination therapy, Second-line therapy or greater) (PO, Capsule) (NCT06047379)
- 28 Aug 2020 No recent reports of development identified for preclinical development in Brain metastases in USA